• 1. 第三軍醫(yī)大學(xué)西南醫(yī)院普通外科(重慶400038)2. 第三軍醫(yī)大學(xué)西南醫(yī)院病理科;

觀測(cè)正常乳腺、乳腺囊性增生病和乳腺癌細(xì)胞核DNA含量、細(xì)胞超微結(jié)構(gòu)、Y抗原及免疫抑制性酸性蛋白(IAP-2)表達(dá)。結(jié)果：上皮增生Ⅰ級(jí)細(xì)胞與正常乳腺細(xì)胞相似；不典型增生細(xì)胞DNA含量增加，細(xì)胞膜和細(xì)胞核超微結(jié)構(gòu)出現(xiàn)發(fā)育不良及去分化現(xiàn)象，部分不典型增生細(xì)胞見(jiàn)異?？乖磉_(dá)；部分Ⅲ級(jí)不典型增生細(xì)胞DNA含量和超微結(jié)構(gòu)與乳腺癌組織分化Ⅰ級(jí)細(xì)胞相似。提示在不典型增生階段，這些細(xì)胞的生物學(xué)異常和程度與其細(xì)胞分化程度、發(fā)展趨勢(shì)和癌變危險(xiǎn)性大小密切相關(guān)。

引用本文： 姜軍,詹新恩,陳意生,柳鳳軒,馬宏敏. 乳腺上皮不典型增生時(shí)DNA含量、超微結(jié)構(gòu)及腫瘤相關(guān)抗原變化的意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 1998, 5(4): 208-210. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Tavassoli FA, Norris. A comparison of the results of longterm follow up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer, 1990; 65(3)∶518.
2. 姜軍，詹新恩，柳鳳軒.乳腺導(dǎo)管不典型增生與癌變的關(guān)系.腫瘤防治研究， 1990； 17(3)∶133.
3. 中華人民共和國(guó)衛(wèi)生部醫(yī)政司編.中國(guó)常見(jiàn)惡性腫瘤診治規(guī)范(第八分冊(cè))乳腺癌.北京：北京醫(yī)科大學(xué)中國(guó)協(xié)和醫(yī)學(xué)院出版社， 1991∶53～57.
4. Vorherr H. Fibrocystic breast disease:pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol, 1986; 154(1)∶161.
5. Dupont WD, Page DL. Risk factors for breast cancer in woman with proliferative breast disease. New Engl J Med, 1985; 312(3)∶146.
6. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer, 1990; 66(6)∶1326.
7. Coon JS, Landay AL, Weinstein RS. Flow cytometric analysis of paraffinembedded tumor，implications for diagnostic pathology. Human Pathol, 1986; 17(5)∶435.
8. Meready RW, Papadimitriou JM. An analysis of DNA cytophotometry on tissue sections in a rat liver model. Anat Quat Cyto, 1983; 5(2)∶117.
9. Lloyd KD. Blood group abtigens as markers for normal differantiation and malignant change in human tissues. Am J Clin Pathol, 1987; 87(1)∶129.
10. Tamura K, Shibata Y, Matsuda Y, et al. Isolation and characterization of an immunosuppressive acidic protein (IAP) from ascitic fluids of cancer patient. Cancer Res, 1981; 41(8)∶3244.
  1. 1. Tavassoli FA, Norris. A comparison of the results of longterm follow up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer, 1990; 65(3)∶518.
  2. 2. 姜軍，詹新恩，柳鳳軒.乳腺導(dǎo)管不典型增生與癌變的關(guān)系.腫瘤防治研究， 1990； 17(3)∶133.
  3. 3. 中華人民共和國(guó)衛(wèi)生部醫(yī)政司編.中國(guó)常見(jiàn)惡性腫瘤診治規(guī)范(第八分冊(cè))乳腺癌.北京：北京醫(yī)科大學(xué)中國(guó)協(xié)和醫(yī)學(xué)院出版社， 1991∶53～57.
  4. 4. Vorherr H. Fibrocystic breast disease:pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol, 1986; 154(1)∶161.
  5. 5. Dupont WD, Page DL. Risk factors for breast cancer in woman with proliferative breast disease. New Engl J Med, 1985; 312(3)∶146.
  6. 6. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer, 1990; 66(6)∶1326.
  7. 7. Coon JS, Landay AL, Weinstein RS. Flow cytometric analysis of paraffinembedded tumor，implications for diagnostic pathology. Human Pathol, 1986; 17(5)∶435.
  8. 8. Meready RW, Papadimitriou JM. An analysis of DNA cytophotometry on tissue sections in a rat liver model. Anat Quat Cyto, 1983; 5(2)∶117.
  9. 9. Lloyd KD. Blood group abtigens as markers for normal differantiation and malignant change in human tissues. Am J Clin Pathol, 1987; 87(1)∶129.
  10. 10. Tamura K, Shibata Y, Matsuda Y, et al. Isolation and characterization of an immunosuppressive acidic protein (IAP) from ascitic fluids of cancer patient. Cancer Res, 1981; 41(8)∶3244.